Olopatadine 0.1%

DRUG2 trials

Sponsors

Alcon Research, Bausch & Lomb Incorporated

Conditions

Allergic ConjunctivitisSeasonal Allergic Conjunctivitis

Phase 3

Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

CompletedNCT01435460

Bausch & Lomb IncorporatedSeasonal Allergic Conjunctivitis

Start: 2010-08-31End: 2011-05-31Updated: 2012-03-13

Phase 4

Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)

CompletedNCT00818805

Alcon ResearchAllergic Conjunctivitis

Start: 2008-07-31Updated: 2012-06-04

Related Papers

Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

2012-05-2317 citations